Dong, Daifeng
Pizzagalli, Diego A. http://orcid.org/0000-0002-7772-1143
Bolton, Thomas A. W.
Ironside, Maria
Zhang, Xiaocui
Li, Chuting
Sun, Xiaoqiang
Xiong, Ge
Cheng, Chang
Wang, Xiang
Yao, Shuqiao
Belleau, Emily L.
Funding for this research was provided by:
Scientific Research Launch Project for New Employees of the Second Xiangya Hospital of Central South University
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH132565, K23MH122668)
National Natural Science Foundation of China (82071532)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Klingenstein Third Generation Foundation
Article History
Received: 19 June 2023
Revised: 1 January 2024
Accepted: 4 January 2024
First Online: 13 January 2024
Competing interests
: Over the past three years, Dr. Pizzagalli has received consulting fees from Albright Stonebridge Group, Boehringer Ingelheim, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics (formerly BlackThorn Therapeutics), Neurocrine Biosciences, Neuroscience Software, Otsuka, Sunovion, and Takeda; he has received honoraria from the Psychonomic Society and American Psychological Association (for editorial work) and from Alkermes; he has received research funding from the Brain and Behavior Research Foundation, Dana Foundation, Millennium Pharmaceuticals, and Wellcome Leap; he has received stock options from Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, and Neuroscience Software. There are no conflicts of interest with the work conducted in this study. No funding from these entities was used to support the current work, and all views expressed are solely those of the authors. The other authors report no financial relationships with commercial interests.